Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. The patent name is “Novel CTHRC1's specific antibody and use thereof."

Following the PAUF (pancreatic adenocarcinoma up-regulated factor) neutralizing antibody patent for the pancreatic cancer drug PBP1510, the company plans to accelerate the development of new solid cancer antibody drugs by securing the additional patent.

It was reported that CTHRC1 was overexpressed in solid cancers such as pancreatic cancer, leading to the formation of cancer. PBP1710 is an antibody drug that specifically binds to and neutralizes the CTHRC1 protein.

This is expected to inhibit the formation of solid tumors. The company explained that this is the first time that a patent has been issued for the treatment of intractable solid cancer for the CTHRC1 antibody in South Korea.

The CTHRC1 neutralizing antibody-related technology was developed by Prestige Biopharma's Innovative Discovery Center (IDC). IDC said it found that the CTHRC1 antibody indeed inhibited the migration or invasion of cancer cells by about 45% or more in solid cancers such as pancreatic cancer and breast cancer.

The company has also applied for patents in 21 countries, including the United States, Japan, and Europe, for the same technology.

Write to Jae-Young Han at jyhan@hankyung.com